Newborn survival

The shape of the fix here is unusually well specified, because the deficient inputs are a short, known list: reliable medical oxygen delivery, pulse oximetry at every bedside where a newborn is being monitored, and a same-day point-of-care sepsis diagnostic, deployed with the maintenance, consumables supply chain, and staff training to keep them functioning past the first six months after installation (the point at which most donated medical equipment in low-resource settings fails, per widely cited WHO device-sustainability estimates). This is a devices-plus-logistics problem, not a drug-discovery problem, which means the development timeline is years, not the decade-plus typical of new pharmaceuticals. The strongest existing proof of concept is NEST360, an alliance operating across Kenya, Malawi, Nigeria, and Tanzania that bundles devices, data systems, and training into hospital neonatal units. A 2026 Lancet Global Health cost analysis of NEST360's rollout found mean incremental cost per baby admitted ranging from $69 in Kenya to $265 in Nigeria, with a blended return of approximately $12 of health benefit for every $1 invested (Lancet Global Health, NEST360 incremental cost analysis, 2026). Separately, cost-effectiveness research on oxygen and pulse-oximetry systems specifically in Nigerian hospitals found a five-year cost of $2,694-$4,382 per life saved (PMC, Nigeria hospital oxygen systems cost-effectiveness study), a figure that compares favorably with almost any other life-saving intervention tracked in global health cost-effectiveness literature. Why this is buildable now: the device costs are already low and mostly solved (a purpose-built low-resource pulse oximeter runs roughly $250, per Lifebox), and the open problem is the last-mile deployment and maintenance layer, which is where recent advances in mobile connectivity, remote device-monitoring (so a broken oxygen concentrator gets flagged and fixed before it causes a death rather than being discovered broken during the next emergency), and digital training tools genuinely change what is operationally possible relative to a decade ago, when device rollouts in this setting had no way to detect failure remotely. The dollar figure, worked directly: an estimated 20-30 million small and sick newborns need inpatient hospital care globally each year (WHO, 2018 estimate, consistently cited in the Lancet small-and-sick-newborn literature). Using the midpoint of NEST360's observed incremental cost range, roughly $100 per baby admitted for a full oxygen, pulse oximetry, diagnostics, and health-systems-strengthening package (Lancet Global Health, 2026, range $69-$265 across four countries), full global coverage at that per-baby cost is a market of approximately $2.5-3 billion a year. That is the size of the addressable market for the devices, consumables, training, and systems-strengthening layer needed to close this gap, not a one-time capital cost but a sustained annual figure, since consumables, maintenance, and staff turnover mean this is a recurring, not one-time, spend. That $2.5-3 billion/year figure sits well above the $60 million funding gap identified by the Center for Global Development specifically for one component, a rapid neonatal sepsis diagnostic (CGD, NeoTest, 2024), which is a narrower, near-term unlock: fund that one advance market commitment and a specific diagnostic tool that does not currently exist commercially gets built. The $2.5-3B figure is the fuller systems-level market once oxygen delivery, pulse oximetry, and diagnostics are considered together across all facilities that need them, not one device category in isolation. Confidence note: the per-baby cost figures come from a real, peer-reviewed multi-country cost analysis (Lancet Global Health, 2026), so the $69-$265 range itself is medium-to-high confidence. The resulting $2.5-3B global market-size figure is a lower-confidence extrapolation, since it assumes the four-country NEST360 cost structure generalizes to the full set of high-burden countries, which the underlying research has not yet directly tested at that scale. What is high confidence: the $2,694-$4,382-per-life-saved figure for oxygen and pulse oximetry alone places this among the most cost-effective health interventions anywhere, evidenced, not hypothetical, and currently unfunded at the scale the evidence justifies.